The first patients have been dosed in a phase 3 trial of an mRNA-based seasonal influenza vaccine developed by Pfizer and BioNTech, which may offer quicker production and greater efficacy t
BioNTech has responded to a patent infringement lawsuit filed by fellow German biotech CureVac over its COVID-19 vaccine, saying it will "vigorously" defend itself.
CureVac and GlaxoSmithKline's first attempt to develop a COVID-19 vaccine was a salutary reminder of the pitfalls in drug development, as the mRNA shot crashed and burned in a clinical tria
A trial of booster vaccinations to protect against COVID-19 has shown that the jab significantly strengthens the body's T-cell immunity against the disease.
Pfizer and BioNTech have formally asked for FDA approval of a third dose of their COVID-19 vaccine BNT162b2 in people aged over 16, as the US prepares to get its booster campaign underway.
CureVac has just had a harsh reminder of the perilous nature of drug development, after reporting that its mRNA-based COVID-19 vaccine was just 47% effective in its 40,000-subject phase 3 t